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The susceptibility of human embryonal cell line NT-2/D1 to replicate human cytomegalovirus (hCMV) is
dependent on retinoic acid (RA) stimulation. Physiological responses to retinoic acid involve two distinct
subfamilies of nuclear receptors, the RA receptors (RARs) and retinoid X receptors (RXRs), which function by
activating transcription as heterodimeric or RXR homodimeric complexes from cis-acting DNA response
elements. At present, it is not clear whether the association between these two classes of receptors can lead to
multiple distinct induction pathways by signalling one or both receptor partners. Here we have determined, by
selectively activating endogenous receptors with novel synthetic ligands specific for either RARs or RXRs, what
ligand interaction is physiological in the retinoid receptor pathways necessary for inducing replication of
hCMV in differentiated embryonal cells. We show that ligand binding to RAR alone is sufficient and that
exclusive ligand activation of RXR is insufficient for inducing replication of hCMV. We also find that
differentiation and inhibition of NT-2/D1 cell growth are promoted by compounds that signal the RAR pathway.
These results provide direct evidence that RAR ligand-mediated physiological responses are separable and
distinct from RXR ligand activation functions. Moreover, our results provide insight into a hormone response
pathway for cellular differentiation that might be coopted by hCMV in the host.
Vitamin A and its derivatives (retinoids) control a variety of
essential biological functions, including growth, reproduction,
and fetal development. Viruses such as human cytomegalovi-
rus (hCMV) may opportunistically use this homeostatic con-
trol molecule of cellular differentiation to advance their own
replication. Retinoid signals are mediated by specific nuclear
receptors that belong to the steroid/thyroid hormone receptor
superfamily. The retinoid receptors are grouped into two sub-
families (retinoic acid [RA] receptors [RARs] and retinoid X
receptors [RXRs]) which function as ligand-inducible tran-
scription factors by interacting with cis-acting DNA acceptor
sites as either heterodimeric RXR-RAR or homodimeric
RXR complexes (11, 17, 18, 21, 22, 30, 31, 42). These two
receptor subfamilies mediate the cellular responses to two
distinct RA isomers, all-trans RA (ATRA) and 9-cis RA (1, 2,
16, 23, 28, 41). Additionally, RXR forms heterodimeric com-
plexes with other members of the receptor family, including
thyroid hormone, vitamin D, and peroxisome proliferation re-
ceptors (17, 18, 22, 30, 42, 44). The ATRA isomer binds spe-
cifically to members of the RAR subfamily, whereas 9-cis RA
functions as a pan-agonist in that it binds directly to all of the
RXR and RAR subtypes (9, 16, 23, 28). The discovery of
multiple retinoid receptors and RA isomers raises questions of
the potential redundancy and biological roles of the distinct
subfamilies. At present, it is not clear whether the association
between these two classes of receptors can mediate different
induction pathways.
hCMV contains a primary target promoter for RA transcrip-
tional activation (13) and is dependent on RA stimulation for
replication in embryonal carcinoma (NT-2/D1) cells (15). In
addition, recent experimental evidence indicates that RA can
modulate hCMV expression and replication in other cell sys-
tems (4, 40). Consequently, this virus provides a particularly
useful tool for detecting functional features of retinoid signal-
ling pathways. The effect of RA on the progress of hCMV
infection in NT-2/D1 cells is initially determined by the level of
transcription from the major immediate-early promoter
(MIEP) of the virus (32). This promoter contains RA-respon-
sive elements that function as specific target sites for the direct
interaction of RXR-RAR heterodimers (4, 13) and additional
cis-acting sequences which secondarily respond to RA by de-
repression (33, 36). Therefore, stimulation of hCMV replica-
tion in NT-2/D1 cells most probably arises from a direct effect
of RA on the virus as well as being a consequence of the
differentiation of the cells. Retinoids may be of significance in
the pathogenesis of hCMV as a correlation in the temporal,
and spatial patterns of hCMV expression with the physiologic
action of RA in both neonates and adults has been noted (7,
13).
NT-2/D1 cells are known to express the two retinoid recep-
tor subfamilies, RAR and RXR (4, 35). In these cells, both of
the naturally occurring RA isomers, ATRA (15) and 9-cis RA
(4), induce replication of hCMV, reduce the proliferative ca-
pacity of the cells, and promote cell differentiation. Although
ATRA binds only to members of the RAR subfamily, in living
cells it can be converted to 9-cis RA, which indirectly results in
its ability to modulate the functional properties of the RXR
subfamily (16, 28). In addition, 9-cis RA can bind with high
affinity to both RAR and RXR subtypes. Thus, it is not clear
which of the three possible ligand-activated receptor pathways
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(RAR, RXR, or RXR-RAR mediated) leads to replication of
hCMV and cellular differentiation and growth. Here we have
sought to dissect retinoid signalling pathways by relating dif-
ferent synthetic retinoids to the replication of hCMV and cel-
lular differentiation and growth. We find that viral replication
in NT-2/D1 cells is stimulated by ligands that signal the acti-
vation of the RAR pathway. Compounds that activate the
RAR pathway were also found to be sufficient for inducing
differentiation and antiproliferation of the embryonal cells,
indicating that hCMV exploits a primary retinoid signalling
pathway of the cell.
MATERIALS AND METHODS
Retinoids. ATRA was purchased from Sigma. (E)-4-[2-(5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB) and (E)-4-
[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-propenyl]benzoic
acid (3-MeTTNPB) were prepared as previously described (9, 24). 4-[(3,5,5,8,8-
Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)carbonyl]benzoic acid (LG100064)
and4-[1-(3-bromo-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthy)ethenyl]ben-
zoic acid (LG100147) were synthesized as described previously (10). All com-
pounds gave good elemental analyses. The structures of the natural and synthetic
retinoids used in this study are shown in Fig. 1. Stock solutions were prepared in
dimethyl sulfoxide and/or ethanol and stored under argon at 2708C. Further
dilutions were made in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with charcoal resin-treated fetal bovine serum before use. Handling of
retinoids was carried out in subdued lighting, and all containers, tissue culture
flasks, and plates containing retinoids were covered with aluminum foil.
Virus and cells. The Towne strain of hCMV was used throughout this study.
The virus stock was prepared in human foreskin fibroblasts (HFF) by infection at
a low multiplicity. All cell lines were maintained in DMEM supplemented with
10% fetal bovine serum, 2 mM glutamine, 100 U of penicillin per ml, and 100 mg
of gentamicin per ml.
Plasmids and transfections. The receptor expression vectors pRShRARa (14)
and pRShRXRa (28), used in the cotransfection assay, and the reporter plasmids
MTV-TREp2-LUC (38), containing two copies of the palindromic thyroid hor-
mone response element, and the CRBPII-tk-LUC (29), carrying the CRBPII
(cellular retinol-binding protein II) response element, have been described else-
where. hCMV MIEP-RARE-tk-LUC, containing an hCMV RA response ele-
ment of the MIEP (13), was constructed by replacing a HindIII-BglII fragment
from pRARE(cd) (13) in the tk-LUC vector (29). CV-1 cells were transfected by
the calcium phosphate coprecipitation method in 96-well plates for 6 h as de-
scribed previously (8). In each transfection reaction, 20 mg of DNA per ml of
transfection buffer was used. Plasmid ratios used in the specific experiments are
indicated in the figure legends. The cells were incubated for approximately 40 h
with the different ligands. Control transfections received solvent alone. Cell
lysates were prepared as described previously (8) and assayed for luciferase and
b-galactosidase activities. Luciferase activity was expressed as the normalized
response, which is the luciferase activity divided by the b-galactosidase activity.
Detection and quantification of viral DNA and infectious hCMV. Approxi-
mately 2 3 106 NT-2/D1 cells seeded in 25-cm2 flasks were exposed to the
different retinoids diluted in DMEM supplemented with 5% charcoal resin-
treated fetal bovine serum for 5 days and then infected with hCMV (Towne
strain) at a multiplicity of infection (MOI) of 4. After a 3-h adsorption period,
the virus inoculum was removed, the cultures were washed five times with
phosphate-buffered saline (PBS), and fresh DMEM supplemented with 3%
charcoal resin-treated fetal bovine serum containing the retinoids was added. On
days 3 and 6 after infection, the cultures were fed. On various days postinfection,
the cells were harvested and frozen in aliquots in liquid nitrogen. Extracellular
virus was not detected by plaque assay or fluorescence focus assay in the super-
natant of infectious cultures. Total cell DNA was prepared by standard proce-
dures. The DNAs were blotted onto nylon membranes, hybridized with a 32P-
labeled probe corresponding to an HpaI-StuI fragment of the UL122 coding
region of hCMV, and the amount of hybridized radioactive probe per specific
sample was determined by scintillation counting. The assay procedure was vali-
dated by treating infected cells with a specific viral DNA inhibitor (foscarnet)
which quantitatively inhibited the hybridization signal in a dose-response man-
ner.
Quantitation of infectious particles of hCMV was determined by fluorescence
focus assays on HFF. Briefly, the harvested infected NT-2/D1 cells were soni-
cated and plated at various dilutions onto HFF monolayers. After a 2-h adsorp-
tion period, the virus inoculum was removed, cultures were washed five times
with PBS, and fresh medium was added. The cultures were allowed to incubate
for 24 h at 378C. After this incubation period, cells were fixed in methanol for 2
min and reacted with hCMV immediate-early monoclonal antibody 810 (dilution
of 1:60) for 1 h at 378C. The bound antibody was determined by indirect immu-
nofluorescence with a secondary antibody, goat anti-mouse fluorescein conjugate
(dilution of 1:50; Sigma Immunochemicals).
Differentiation marker analyses. The presence of neurofilament in NT-2/D1
cells treated with the different retinoids was assayed by immunofluorescence
microscopy with cells grown on chamber slides and fixed with methanol for 2 min
as previously described (6). An antineurofilament (Mr-200,000 polypeptide) rab-
bit antisera (dilution of 1:100; Chemicon International Inc.) (5) and a goat
anti-rabbit fluorescein conjugate (dilution of 1:50; Sigma Immunochemicals)
were used. The percentage of cells containing neurofilament was determined by
direct counting. Expression of the cell surface antigens (SSEA-3 and A2B5) was
studied by fluorescence-activated cell sorter analysis, using established tech-
niques. NT-2/D1 cells were harvested by trypsinization, and approximately 106
cells were reacted with an anti-SSEA-3 (dilution of 1:2; Developmental Studies
Hybridoma Bank, University of Iowa) (5) or anti-A2B5 (dilution of 1:50; Amer-
ican Type Culture Collection) (5) monoclonal antibody. Cells were then washed
three times, stained with fluorescein-conjugated goat anti-mouse secondary an-
tibody, and washed again, and fluorescence was measured by flow cytofluorim-
etry using a FACScan (Becton Dickinson, Mountain View, Calif.).
Proliferation assays. Following 7 days of retinoid treatment, the NT-2/D1 cells
were seeded at a density of 2 3 104 cells per well of 96-well plates. Cells were
incubated at 378C for 16 h with 50 ml of [3H]thymidine (10 mCi/ml; 5 Ci/mmol)
in DMEM supplemented with 5% charcoal resin-treated fetal bovine serum.
FIG. 1. Structures and potency of natural and synthetic retinoid compounds.
CV-1 cells were cotransfected with 1 mg of pRShRARa or pRShRXRa per ml
together with 5 mg of MTV-TREp2-LUC or CRBPII-tk-LUC reporter, respec-
tively, per ml and 5 mg of pRSV-b-gal per ml as an internal control. pGEM4
plasmid DNA (9 mg/ml) was added to bring the final DNA concentration to 20
mg/ml. The cells were incubated for approximately 40 h with increasing concen-
trations of the indicated ligands. Cell lysates were prepared and assayed for
luciferase and b-galactosidase activities. Luciferase activity is expressed as the
normalized response, which is the luciferase activity divided by the b-galactosi-
dase activity. The EC50 value is defined as the concentration of ligand giving 50%
of the maximal observed effect upon transcription of the luciferase reporter. The
data shown represent the means 6 standard errors of the means of at least three
independent EC50 determinations. Similar results were obtained in RARb or -g
and RXRb or -g cotransfection experiments.
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After this time, cells were washed extensively with PBS and harvested after
addition of 50 ml of 3% sodium dodecyl sulfate. The amount of specific thymi-
dine incorporation per well was determined by scintillation counting.
RESULTS
Synthetic RA analogs that are highly selective and potent
ligands for activating RAR and RXR subfamilies. Physiologi-
cal responses to RA involve two distinct subfamilies of nuclear
receptors, RARs and RXRs. These receptors activate tran-
scription as RXR homodimeric or heterodimeric complexes
that bind to specific sequences at or near promoters. We have
synthesized several novel chemical analogs of RA that have the
specific property of activating either RARs, RXRs, or both, as
shown in the following set of experiments (Fig. 1). We mea-
sured the selectivity of these compounds to activate RAR- or
RXR-mediated transcription by a coupled plasmid transfec-
tion assay (Fig. 1). In this assay, we introduced an expression
vector for the indicated retinoid receptor along with a reporter
construct carrying either the thyroid hormone response ele-
ment (TRE-pal-RARE) or CRBPII (CRBPII-RXRE) (1). The
TRE-pal-RARE reporter has been shown to be dependent on
cotransfection of RAR expression vectors for activation, while
the reporter CRBPII-RXRE has been demonstrated to be
exclusively activated by and dependent on cotransfection of
RXR expression vectors (29, 45). Therefore, this coupled plas-
mid transfection assay is well suited for determining the selec-
tivity and potency of compounds that activate RAR or RXR
transcriptional pathways. The potency (concentration of reti-
noid that produced 50% of the maximal response [EC50]) of
the retinoids was determined by varying their concentration
over 8 orders of magnitude (from 10212 to 1025 M). As ex-
pected, ATRA, 9-cis RA, and the pan-agonist 3-MeTTNPB
were capable of inducing reporter activity mediated by both
RAR and RXR induction pathways (Fig. 1). As previously
reported (16, 28), the RAR-selective ligand (TTNPB) was
shown to be a potent activator of RAR (EC50 of 30 nM) and
was unable to effect activation of RXR (Fig. 1). By contrast,
LG100064 and LG100147 selectively activated RXR with EC50
values of 379 and 51 nM, respectively (Fig. 1). These data
demonstrate the RAR selectivity of TTNPB and the RXR
selectivity of LG100064 and LG100147. Importantly, the use of
these metabolically stable compounds provides a unique tool
to modulate, in the cell, distinct retinoid signalling pathways.
Exclusive induction of the RAR pathway is sufficient for
activating the cytomegalovirus RA response element. Previ-
ously we found that the MIEP of hCMV contains an RA
response element (13). This element is composed of two direct
repeat motifs separated by five nucleotides and is activated by
the binding of endogenous RAR-RXR heterodimers (4, 13).
Because RAR alone is unable to bind the viral RA response
element with high affinity (4), these studies demonstrate that
NT-2/D1 cells express a functional retinoid receptor complex
of both RARs and RXRs, which can be transactivated by RA.
In the following experiments, we use the synthetic retinoid
compounds characterized above to demonstrate what retinoid
signalling pathway is operative in activation of the viral RA
response element. The assay used a plasmid construct that
contained the hCMV MIEP RA response element fused to a
luciferase reporter gene (13). The reporter gene activities mea-
sured when various synthetic retinoids were added to the trans-
fected cells are shown in Fig. 2. The viral reporter was acti-
vated by both 3-MeTTNPB and TTNPB but not by the RXR-
selective compounds LG100064 and LG100147 (Fig. 2).
Cotransfection of expression vectors for RAR, RXR, or both
yielded the same dose-response curves for each of the ligands
(4). These experiments reveal the potency of TTNPB in RAR
activation of the viral response element and the inability of
RXR to contribute exclusively to ligand activation, suggesting
a restricted dependence of the hCMV promoter element on
RAR transactivation functions. These results (Fig. 1 and 2) are
in agreement with those of previously published cotransfection
assays indicating that RAR and RXR may differentially medi-
ate distinct retinoid induction pathways (11, 12, 17, 18, 20–22,
25–27, 30, 31, 39, 42, 44). Importantly, one can specifically
address how these retinoids stimulate hCMV replication in
NT-2/D1 cells, and thus this model provides a unique oppor-
tunity for directly evaluating the physiological response of the
different retinoid receptor pathways.
hCMV replication in NT-2/D1 cells requires activation of
the RAR pathway but fails to replicate upon exclusive stimu-
lation of the RXR pathway. The replication of hCMV in NT-
2/D1 cells has been shown to be dependent on RA stimulation
(15). Accordingly, we sought to determine whether the RAR
pathway characterized above for the viral RA response ele-
ment is also necessary for inducing replication of hCMV. In
the following set of experiments, retinoid stimulation of hCMV
was monitored by examining viral replication in infected NT-
2/D1 cells in the presence of the different synthetic com-
pounds. Viral DNA replication was determined by slot blot
analysis at different times postinfection. As expected, hCMV
failed to replicate with solvent alone, but in the presence of
ATRA, a dramatic induction (;104 genome equivalents per
cell) of viral replication was exhibited (Fig. 3). Similarly, treat-
ment of NT-2/D1 cells (which coexpress RAR and RXR sub-
FIG. 2. Transactivation of the hCMV MIEP RA response element by syn-
thetic retinoids. CV-1 cells were cotransfected with 5 mg of hCMV MIEP-
RARE-tk-LUC reporter per ml together with 5 mg of pRSV-b-gal per ml and
pGEM4 to bring the final plasmid concentration to 20 mg/ml. The cells were
incubated for approximately 40 h with increasing concentrations of TTNPB
[RAR (L)], 3-MeTTNPB [RAR/RXR (L)], L100064 [RXRa (L)], or LG100147
[RXRb (L)]. The data are presented as normalized responses calculated as
indicated in the legend to Fig. 1. Data shown represent the means6 the standard
errors of the means of triplicate determinations. Similar results were obtained in
cotransfection experiments with RARa or -b or RXRa and in dual cotransfec-
tion assays with RARa or -b and RXRa except that the observed normalized
response was enhanced.
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families [4, 35]) with the pan-agonist 3-MeTTNPB also led to
replication of hCMV (Fig. 3), with a half-maximal induction
observed at ;50 nM (Fig. 4). It should be noted that hCMV
replication was not induced to a significantly higher level by
3-MeTTNPB than by ATRA under the conditions of these
NT-2/D1 cell infection experiments.
To examine whether an uncoupled activation of RAR and
RXR can lead to hCMV replication, NT-2/D1 cells were
treated with either TTNPB or LG100064. The RAR-selective
ligand (TTNPB) induced viral DNA replication to levels (;104
genome equivalents per cell) comparable to those found for
ATRA, thus directly implicating RAR activation functions in
hCMV replication (Fig. 3). Half-maximal induction of hCMV
replication was observed at ;5 nM for TTNPB (Fig. 4), in
agreement with the EC50 value observed in the retinoid-in-
duced transactivation assays (Fig. 1 and 2). In marked contrast,
two structurally dissimilar compounds (LG100064 and
LG100147) with similar activities for RXR activation failed to
yield significant viral replication (,1 genome equivalent per
cell), indicating that ligand binding to RAR alone is sufficient,
and exclusive ligand activation of RXR pathways is insufficient,
for inducing hCMV replication (Fig. 3).
Further, to determine whether induction of the RAR path-
way also leads to production of infectious virus in NT-2/D1
cells, infectious fluorescence focus assays were performed. The
results of these experiments (Fig. 5) demonstrate that exposure
of cells to ligands that activate RAR permitted production of
infectious viral particles (;104 fluorescence focus units), while
cells treated with the RXR-selective ligands remained totally
nonpermissive for viral growth. We conclude from these data
that the ligand-induced RAR pathway, but not the RXR path-
way, is sufficient for mediating the retinoid induction of hCMV
replication.
The RAR pathway is sufficient for retinoid-induced differ-
entiation and antiproliferation of NT-2/D1 cells. Retinoids
control a variety of biological processes, including differentia-
tion and proliferation of cells. NT-2/D1 cells differentiate into
cell types of neuronal lineage and retard their growth in the
presence of RA. Thus, the replication competence of hCMV in
RA-treated NT-2/D1 cells may be a consequence of retinoid-
induced differentiation of cells and/or reduced proliferative
capacity. Alternatively, RA may directly induce viral replica-
tion and also initiate cell differentiation and/or antiprolifera-
tion. It is possible that distinct retinoid receptor pathways are
used for viral replication, differentiation, and antiproliferation
FIG. 3. Selective activation of hCMV DNA replication by different retinoids.
NT-2/D1 cells were exposed to ATRA at 1025 M [AT (L)], TTNPB at 1027 M
[RAR (L)], 3-MeTTNPB at 1026 M [RAR/RXR (L)], LG100064 at 1026 M
[RXRa (L)], LG100147 at 1026 M [RXRb (L)], and vehicle (-RA). Subse-
quently, cells were infected with hCMV (Towne) at an MOI of 4. At various days
postinfection (dpi), the cells were harvested and viral DNA was quantified as
described in Materials and Methods. The results, normalized to the number of
cells, are expressed as the amounts (percentages) of viral DNA replication
relative to the maximum level of newly replicated viral DNA detected in NT-
2/D1 cells treated with ATRA (100%). The data represent average values from
two independent experiments.
FIG. 4. Potency of different retinoids on the activation of hCMV DNA rep-
lication. NT-2/D1 cells were treated with ATRA [AT (L)], TTNPB [RAR (L)],
and 3-MeTTNPB [RAR/RXR (L)] at the indicated concentrations. After retin-
oid induction, cells were infected (at an MOI of 4) with hCMV (Towne) and
tested for the presence of viral DNA on day 5 postinfection as described in
Materials and Methods. The results, normalized to the number of cells, are
expressed as percentages of the amounts (counts per minute) of viral DNA
replication relative to the maximum level detected for NT-2/D1 cells treated with
each retinoid. Results of one set of the duplicate replication assays are shown.
FIG. 5. Production of infectious hCMV in NT-2/D1 cells treated with the
different retinoids. NT-2/D1 cells were exposed to ATRA at 1025 M [AT (L)],
TTNPB at 1027 M [RAR (L)], 3-MeTTNPB at 1026 M [RAR/RXR (L)],
LG100064 at 1026 M [RXRa (L)], LG100147 at 1026 M [RXRb (L)], and the
vehicle (-RA). The retinoid-induced cells were infected with the Towne strain of
hCMV (at an MOI of 4) and harvested on day 8 postinfection. Infectious virus
present in the infected NT-2/D1 cells was determined by fluorescence focus assay
on HFF. The number of fluorescence focus units (ffu) of hCMV was determined
as described in Materials and Methods. Data shown correspond to a represen-
tative example of three independent experiments.
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or that their retinoid signalling pathways converge. If the virus
uses a retinoid signalling pathway different from that of differ-
entiation and proliferation, then this would indicate a direct
effect of RA on hCMV. On the other hand, if the cellular
responses (differentiation and proliferation) to RA parallel
those to hCMV replication, then this might indicate an indirect
effect. However, in this case, when all pathways converge, then
one cannot formally exclude a direct involvement of RA with
hCMV. In the following set of experiments, we sought to de-
termine what ligand receptor interaction is required for medi-
ating the cellular responses to RA by exposing NT-2/D1 cells at
various times to the different synthetic ligands and analyzing
them for their state of differentiation and growth.
Differentiation of NT-2/D1 cells following exposure to RA is
indicated by the appearance of the surface marker A2B5 and
neurofilament proteins, which are characteristic of the differ-
entiated cells, and the reduction of expression of the cell sur-
face antigen SSEA-3, characteristic of the embryonal carci-
noma cells (5). As shown in Fig. 6, cells treated with ligands
that activate RAR expressed neurofilament proteins (approx-
imately 60%; Fig. 6A) and induced A2B5 (approximately 90%;
Fig. 6B), while cells treated with RXR-exclusive ligands failed
to express either neurofilament (less than 5% of the cell pop-
ulation; Fig. 6A) or A2B5 (less than 10% of the cell popula-
tion; Fig. 6B). Accordingly, after 6 days of treatment with
ATRA and 3-MeTTNPB, approximately 90% of cells ceased
to express the SSEA-3 antigen. Treatment of the NT-2/D1 cells
with the RAR-selective ligand TTNPB for 6 days caused the
disappearance of ;60% of the SSEA-3 marker, while no re-
duction in SSEA-3 expression resulted from exposure to the
RXR-selective ligands. We also studied the expression of the
Hox 2.9 homeobox gene, which is known to be rapidly and
specifically induced by RA in NT-2/D1 cells (37). In agreement
with the differentiation data, we also observed the requirement
of RAR but not exclusive RXR activation of Hox 2.9 expres-
sion after exposure to retinoids (3).
Finally, to determine whether RAR activation also leads to
an antiproliferative response, NT-2/D1 cells were exposed to
the different synthetic RA analogs and examined for their state
of proliferation. Ligands that activate RAR inhibited efficiently
the proliferation of NT-2/D1 cells (Fig. 7). By contrast, ligands
FIG. 6. Expression of neurofilament and surface antigens SSEA-3 and A2B5 in NT-2/D1 cells exposed to different retinoids. NT-2/D1 cells were treated with ATRA
at 1025 M [AT (L)], TTNPB at 1026 M [RAR (L)], 3-MeTTNPB at 1026 M [RAR/RXR (L)], LG100064 at 1026 M [RXRa (L)], LG100147 at 1026 M [RXRb (L)],
or the vehicle (-RA). At various days after retinoid treatment (dpt), the cultures were either fixed and tested by immunofluorescence microscopy for neurofilament
positive cells (A) or trypsinized and assayed by flow cytofluorimetry for the expression of A2B5 (B) and of the SSEA-3 (C) antigens, using the corresponding antibodies
as indicated in Materials and Methods. Results of one set of the duplicate immunofluorescence assays are shown.
FIG. 7. Effect of different retinoids on NT-2/D1 cell proliferation. NT-2/D1
cells that were exposed to ATRA at 1025 M [AT (L)], TTNPB at 1026 M [RAR
(L)], 3-MeTTNPB at 1026 M [RAR/RXR (L)], LG100064 at 1026 M [RXRa
(L)], LG100147 at 1026 M [RXRb (L)], or the vehicle (-RA) were seeded at a
density of 2 3 104 cells per well in 96-well plates and assayed for the capability
to incorporate [3H]thymidine during 16 h as an index of proliferation. The results
are expressed as the normalized proliferation response, which is the percentage
of proliferation developed by cells treated with the different retinoids relative to
the proliferation of cells that received solvent alone. The data shown represent
the means of two independent experiments.
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that exclusively activate RXR failed to slow the growth rate of
this cell line (Fig. 7). Thus, in NT-2/D1 cells, retinoid control of
proliferation also appears to depend on RAR transactivation
functions.
Together, these experiments indicate that cells treated with
ligands that activate RAR promote differentiation and anti-
proliferation, while exclusive activation of RXR is not suffi-
cient to effect a response. Thus, the observed divergent effects
of RAR and RXR ligand-activated pathways are not unique to
the virus and might indicate a requirement for cellular differ-
entiation in viral replication.
DISCUSSION
Here we show, by using novel synthetic retinoids, that ligand
activation of the RAR pathway but not the interconnected
RXR pathway is a prerequisite to replicate hCMV in NT-2/D1
cells. Concordant with viral growth, we also find that differen-
tiation and antiproliferation of NT-2/D1 cells are induced by
compounds that mediate RAR transcriptional activation but
not by compounds that signal RXR activation. We interpret
this result to mean that the RXR pathway is not required in
these cells for RA-mediated differentiation and growth pro-
cesses. These findings have important implications for under-
standing the action of retinoids relevant to viral biology and
hormone receptor function.
In humans, reactivation of hCMV may be frequent and,
depending on the immune status of the individual, may or may
not be associated with disease. Vitamin response pathways
represent one of perhaps many different physiological stimuli
that might influence viral activation. Previously, we have spec-
ulated on the possible involvement of vitamin A (RA) as a
potential modulator of hCMV replication in vivo (see the in-
troduction and reference 13). Although it remains to be deter-
mined whether retinoids are used by hCMV in humans, the
identification of the RAR pathway in this study is an important
step in defining a molecular pathway used by the cell which is
coopted by hCMV for its replication. The question of direct
activation of hCMV by retinoids is complicated, since the slow
growth kinetics of hCMV coincide with the differentiation of
the cells by retinoids. Experiments examining differentiation
markers revealed that RA-induced differentiation of NT-2/D1
cells requires only RAR activation functions, indicating that
these effects are not virus specific and may be indirect. How-
ever, consistent with a direct effect and in agreement with the
viral replication data, we find that the MIEP of hCMV is
selectively activated by RAR through the RAR-RXR het-
erodimer complex. Further, the role of the RAR-selective
pathway for hCMV replication does not appear to be depen-
dent on differentiation or restricted to NT-2/D1 cells, as our
recent experimental evidence indicates that RAR but not
RXR activation can lead to enhanced replication in HFF (4).
In addition, retinoids have been shown to up-regulate hCMV
expression in latently infected glioblastoma (U138-MG) cells
(40). Combined, these observations lend support to both a
direct and an indirect effect of RA action on hCMV. In the
case of NT-2/D1 cells, a plausible explanation for our observed
results is that RA directly activates MIEP transcription and
induces (represses) the expression of a select subset of cellular
genes via RAR-RXR heterodimers. These induced (sup-
pressed) gene products, in combination with direct activation
by the retinoid receptors, stimulate differentiation and hCMV
expression, leading to viral replication in the differentiated
cells. Regardless of the underlying mechanism responsible for
the replication potential of hCMV in NT-2/D1 cells, the ob-
served viral replication and nonreplication mediated by RAR
and RXR pathways, respectively, demonstrate a dramatic func-
tional difference between the interconnected retinoid receptor
pathways.
RA is required for growth, morphogenesis, differentiation,
and homeostasis (see the introduction). In addition to viral
replication, our findings indicate that the activation of RAR
alone is sufficient for inducing cellular differentiation and ces-
sation of cell proliferation. While previous studies have estab-
lished that RAR functions as a heterodimeric complex with
RXR (12, 20, 25, 26, 44), our results clearly document that the
biological activation function of RAR is separable from that of
RXR. The precise mechanism by which RAR but not RXR
exclusively affects activation functions in RXR-RAR het-
erodimeric complexes remains to be elucidated. The lack of
activity of the RXR component of RXR–COUP-TF and RXR-
thyroid hormone receptor heterodimers may involve similar
mechanisms (17, 30, 34). A recent study has indicated that the
polarity of RXR-RAR heterodimers directs ligand binding and
sensitivity of transactivation (19). In this study, the binding
polarity of heterodimers formed by RXR with RAR on direct
repeats spaced by five nucleotides was shown to be fixed in
59-RXR-RAR-39 orientation (19, 43), and ligand bound exclu-
sively to the downstream receptor (19). In this connection, the
hCMV RA response element has an identical spacer length
and is selectively bound by heterodimers that are likely to be
fixed in 59-RXR-RAR-39 orientation. Therefore, our observa-
tions are in good agreement with, and most likely related to,
the binding polarity of heterodimers formed by RXR and
RAR. Combined with many other studies (1, 2, 11, 12, 16–18,
20–23, 25–31, 39, 41, 42, 44, 45), our findings support the
notion that specificity in retinoid receptor function is achieved
by not only selective DNA recognition of distinct response
elements but also selective ligand-mediated activation func-
tions.
In summary, our results document the essential role of only
one partner (RAR) within heterodimeric (RXR-RAR) com-
plexes in mediating activation functions and susceptibility of
NT-2/D1 cells to hCMV replication. These observations are
relevant for understanding the role of the receptor subfamilies
in the complex biology of retinoid action and also for providing
insight into the regulation of an important human pathogen,
hCMV.
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